Clarifying the survival impact of immunotherapy in HR+/HER2- metastatic breast cancer: methodological caveats from a real-world perspective--letter to the editor.

No abstract is available for this paper.

• Publication year

  2025

• Venue

  International Journal of Surgery

• Publication date

  2025-11-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/JS9.0000000000003758PMID 41208611
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Favorable outcome of immunotherapy use in metastatic HR+/HER2− breast cancer: a population-based cohort study

  2025cited by this paper
• Accounting for Competing Risks in Clinical Research.

  2024cited by this paper
• Dose modification rules and availability of growth factor support: A cross-sectional study of head-to-head cancer trials used for US FDA approval from 2009 to 2021.

  2022cited by this paper
• Using Propensity Score Matching to Balance the Baseline Characteristics.

  2021cited by this paper
• The impact of comorbidity on cancer and its treatment

  2016cited by this paper

• No citing papers are available for this paper.